ClinicalTrials.gg
CompletedNCT00811928Updated Apr 7, 2017Results posted

Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)

A Phase 3 interventional study of Posaconazole and Fluconazole in Leukopenia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A randomized, open label parallel controlled, multicenter study to evaluate safety and efficacy of Posaconazole oral suspension vs Fluconazole (capsule) in high-risk leukopenic patients for prevention of invasive fungal infection

02

Conditions studied

  • Leukopenia

Browse trials for

Keywords

  • high-risk leukopenic patients
03

In context

Leukopenia

30 studies on the registry are indexed under Leukopenia; 7 are open to participants now.

This study's enrollment of 252 is above the median of 57 across 18 interventional studies indexed under Leukopenia.

Browse Leukopenia studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18-70 years of age of either sex
  • Persistent neutropenia ( [ANC] \< 500/mm\^3 [0.5x10\^9/L])or probable neutropenia in 3-5 days is anticipated. Neutropenia >= 7 days caused by the following reasons

    • Standard or dose-intense chemotherapy, anthracyclines or other acceptable chemotherapies ( any drug is not permitted) for Acute Myelogenous Leukemia (AML) treatment
    • Retreatment of chemotherapy in case of AML recurrence
    • Myelodysplastic syndrome (MDS) shifts to AML and bone marrow arrest induction chemotherapy is required (not including acute phase of chronic myelogenous leukemia [CML])
  • obtained from participant or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Participants previously treated with amphotericin B (AMB), fluconazole (FLZ), or itraconazole (ITZ) within 30 days of enrollment.
  • Participants who have taken the following drugs:

    • terfenadine, cisapride, and ebastine within 24 hours before entry
    • astemizole at entry or within 10 days before entry
    • cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry
  • The above drugs are refrained during the investigation
  • Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate \<60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.
  • Participants who have used any drugs or biologic agents other than their chemotherapy regimens within 30 days of study entry.
  • Prior enrollment in this study.
  • Participants with known or suspected or idiosyncratic reaction to azole agents or amphotericin B.
  • Participants with known or suspected invasive fungal infection (IFI) at screen
  • Participants with severe renal insufficiency (estimated less than 50 mL/minute or likely to require dialysis during the study), (ALT), Aspartate transaminase (AST), alkaline phosphatase or total are >2× () ULN.
  • Participants having an (ECG) with a prolonged : QTc greater than 450 msec for men and greater than 470 msec for women.
  • Participants with AML or CML history.
  • Participants with a history of allogeneic hematopoietic stem cell, bone marrow transplantation, stem cell transplantation history.
  • Female participants who are pregnant or are nursing.
  • Alcohol and/or drug abuse.
  • Participants cannot be compliant in the opinion of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Active comparator
    Posaconazole

    Posaconazole oral suspension 200 mg three times a day (TID)

    Drug: Posaconazole

  • Active comparator
    Fluconazole

    Fluconazole 400 mg once daily (QD)

    Drug: Fluconazole

Interventions

  • 40 mg/mL; 200 mg (5 mL) TID Treatment was continued with each cycle of chemotherapy until: * The onset of a proven or probable diagnosis of invasive fungal infection (IFI) * 3 chemotherapy cycles or * Total treatment duration up to 12 weeks (84 days)

    Also known as: Noxafil, SCH 056592

  • 50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules); 400 mg QD Treatment was continued with each cycle of chemotherapy until: * The onset of a proven or probable diagnosis of invasive fungal infection (IFI) * 3 chemotherapy cycles or * Total treatment duration up to 12 weeks (84 days)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period

    Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks \[84 days\]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

    Time frame: Up to 12 Weeks (84 days) plus 7 days

Secondary outcomes

  1. Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization

    Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

    Time frame: From randomization date to Day 100

  2. Time From Randomization to the First Onset of Proven or Probable IFI

    The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms.

    Time frame: From randomization date to Day 100

  3. Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy

    The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

    Time frame: Up to 12 weeks (84 days)

  4. Number of Participants With Clinical Failure During Treatment

    Clinical failure was defined as follows: * Presence of a proven or probable IFI * Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total * Discontinuation due to adverse event (AE) possibly or probably related to study drug * Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase

    Time frame: Up to 12 weeks (84 days)

  5. Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization

    Death from any cause.

    Time frame: Randomization date to Day 100

  6. Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization

    Exact Causes of Death and Their Relationship to IFI Episode Were As Follows: * Unlikely related: participant completed treatment and cause of death was due to primary disease or complication * Possibly related: IFI undergoing treatment without stabilization, or with failure to have a complete remission, where cause of death might have been due to IFI, including progression or relapse of primary disease * Probably related: autopsy or clinical signs suggested that progression of IFI was the probable cause of death

    Time frame: From randomization date to Day 100

07

Results

Posted Sep 13, 2011

Participant flow

Participant flow — Overall Study
MilestonePosaconazoleFluconazole
Started129123
Completed9090
Not completed3933
Withdrew: Aes and saes including death711
Withdrew: Withdrawal by subject1812
Withdrew: Did not take study drug30
Withdrew: Without primary efficacy endpoint data74
Withdrew: Investigator decision21
Withdrew: Poor compliance25

Outcome measures

PrimaryNumber of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period

Number of participants developing a proven or probable IFI from randomization to the last dosage date (up to 12 weeks \[84 days\]) plus 7 days. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

Time frame:
Up to 12 Weeks (84 days) plus 7 days
Reported as:
Number · participants
Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period
participantsPosaconazoleFluconazole
Number of Participants With Proven or Probable Diagnosis of Invasive Fungal Infection (IFI) During the Treatment Period411
Statistical analysis
  • Posaconazole vs Fluconazole · Difference for the incidence: -5.88 · 95% CI -12.21 to 0.25Posaconazole minus fluconazole
SecondaryNumber of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization

Number of participants who developed a proven or probable IFI from randomization date to Day 100 of follow-up visit. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

Time frame:
From randomization date to Day 100
Reported as:
Number · participants
Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization
participantsPosaconazoleFluconazole
Number of Participants With Proven or Probable Diagnosis of IFI Within 100 Days From Randomization516
Statistical analysis
  • Posaconazole · Percentage of participants: 4.27 · 95% CI 1.4 to 9.7IFI Incidence for the Posaconazole group = (# of participants affected with proven or probable IFI/ # of participants in the FAS population at risk)\*100%
  • Fluconazole · Percentage of participants: 13.68 · 95% CI 8.0 to 21.3IFI Incidence for the Fluconazole group = (# of participants affected with proven or probable IFI/ # of participants in the FAS population at risk)\*100%
SecondaryTime From Randomization to the First Onset of Proven or Probable IFI

The time measured in days to the first occurrence of proven/probable IFI diagnosis in the entire FAS population from randomization to Day 100 of follow-up visit. Participants may not have accepted immediate antifungal treatment and later received antifungal treatment based upon further investigator review of the participant's IFI condition. IFI diagnosis criteria may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, positive blood/biopsy cultures with corresponding clinical signs and symptoms.

Time frame:
From randomization date to Day 100
Reported as:
Number · Days
Time From Randomization to the First Onset of Proven or Probable IFI
DaysPosaconazoleFluconazole
Time From Randomization to the First Onset of Proven or Probable IFI82
SecondaryTime From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy

The time measured in days from randomization to the administration of the first concomitant systemic anti-fungal therapy in the entire FAS population. Not all participants who accepted systemic anti-fungal therapy may have had a IFI clinical diagnosis. IFI diagnosis criteria for antifungal therapy administration may include: persistent fever, failure of appropriate broad-spectrum antibiotic treatment concomitant with lower respiratory tract infection symptoms, microbiological criteria with corresponding clinical signs and symptoms.

Time frame:
Up to 12 weeks (84 days)
Reported as:
Number · Days
Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy
DaysPosaconazoleFluconazole
Time From Randomization to Administration of First Systemic Antifungal Intravenous (IV) Therapy41
SecondaryNumber of Participants With Clinical Failure During Treatment

Clinical failure was defined as follows: * Presence of a proven or probable IFI * Systemic antifungal treatment (IV) for 4 consecutive days or more than 10 days total * Discontinuation due to adverse event (AE) possibly or probably related to study drug * Lost-to-follow-up or discontinuation from the study for any reason with loss to follow-up during the Treatment Phase

Time frame:
Up to 12 weeks (84 days)
Reported as:
Number · participants
Number of Participants With Clinical Failure During Treatment
participantsPosaconazoleFluconazole
Number of Participants With Clinical Failure During Treatment3751
Statistical analysis
  • Posaconazole · Percentage of participants: 31.62 · 95% CI 23.3 to 40.9IFI Incidence for the Posaconazole group = (# of participants affected with proven or probable IFI/ # of participants in the FAS population at risk)\*100%.
  • Fluconazole · Percentage of participants: 41.88 · 95% CI 32.8 to 51.4IFI Incidence for the Fluconazole group = (# of participants affected with proven or probable IFI/ # of participants in the FAS population at risk)\*100%
SecondaryNumber of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization

Death from any cause.

Time frame:
Randomization date to Day 100
Reported as:
Number · participants
Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization
participantsPosaconazoleFluconazole
Number of Participants in Whom All-cause Mortality Occurred Within 100 Days From Randomization38
Statistical analysis
  • Posaconazole · Percentage of participants: 2.56 · 95% CI 0.5 to 7.3All-Cause Mortality Rate is the percentage of participants with mortality from any cause.
  • Fluconazole · Percentage of participants: 5.98 · 95% CI 2.4 to 11.9All-Cause Mortality Rate is the percentage of participants with mortality from any cause.
SecondaryNumber of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization

Exact Causes of Death and Their Relationship to IFI Episode Were As Follows: * Unlikely related: participant completed treatment and cause of death was due to primary disease or complication * Possibly related: IFI undergoing treatment without stabilization, or with failure to have a complete remission, where cause of death might have been due to IFI, including progression or relapse of primary disease * Probably related: autopsy or clinical signs suggested that progression of IFI was the probable cause of death

Time frame:
From randomization date to Day 100
Reported as:
Number · participants
Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization
participantsPosaconazoleFluconazole
Number of Participants in Whom Mortality is Unlikely, Possibly, and Probably Related to Fungal Infection Occurred Within 100 Days From Randomization00

Adverse events

Collected over From screening to the last dosage date plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Posaconazole—7/124 (5.6%)82/124 (66.1%)
Fluconazole—10/121 (8.3%)81/121 (66.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPosaconazoleFluconazole
DeathGeneral disorders1/1242/121
Cerebral haemorrhageVascular disorders2/1241/121
Bone marrow depressionBlood and lymphatic system disorders1/1241/121
Intestinal haemorrhageGastrointestinal disorders0/1241/121
SepsisInfections and infestations1/1241/121
Septic shockInfections and infestations0/1241/121
Cerebellar haemorrhageNervous system disorders0/1241/121
Consciousness disturbanceNervous system disorders0/1241/121
Respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/1241/121
OedemaGeneral disorders1/1240/121
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPosaconazoleFluconazole
PyrexiaGeneral disorders39/12439/121
Hepatic function abnormalInvestigations25/12421/121
ENT disorderRespiratory, thoracic and mediastinal disorders23/12420/121
Electrolyte imbalanceMetabolism and nutrition disorders20/12415/121
RashSkin and subcutaneous tissue disorders19/12419/121
GingivitisGastrointestinal disorders19/12418/121
DiarrhoeaGastrointestinal disorders15/12417/121
Respiratory tract infectionRespiratory, thoracic and mediastinal disorders17/12416/121
NauseaGastrointestinal disorders16/12415/121
Anal disorderGastrointestinal disorders11/12414/121

Baseline characteristics

Age, Continuous
Age, Continuous(participants)PosaconazoleFluconazoleTotal
Mean39.3 ± 13.0140.6 ± 12.5040.4 ± 12.73
Sex: Female, Male
Sex: Female, Male(Participants)PosaconazoleFluconazoleTotal
Female6265127
Male5552107
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shen Y, Huang XJ, Wang JX, Jin J, Hu JD, Yu K, Wu DP, Wang SJ, Yu L, Chen XQ, Liu T, Liang YM, Chen FP, Li Y, Shen ZX. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther. 2013 Sep;51(9):738-45. doi: 10.5414/CP201880. PubMed 23924680 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 1 year 4 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 19, 2008
Start
Nov 2008
Primary completionActual
May 2010
CompletionActual
May 2010
Results delay requested
Apr 27, 2011
Results first posted
Sep 13, 2011
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00811928
Responsible party
Sponsor
First posted
Dec 19, 2008
Start date
Nov 2008
Primary completion
May 2010
Completion
May 2010
Results posted
Sep 13, 2011
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Posaconazole · Fluconazole

Start the discussion